Stock Events

Rezolute 

$4.69
10
+$0.01+0.21% Friday 19:54

Statistics

Day High
-
Day Low
-
52W High
6.1
52W Low
0.72
Volume
175,526
Avg. Volume
288,314
Mkt Cap
187.03M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

15MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.38
-0.32
-0.25
-0.19
Expected EPS
-0.31
Actual EPS
-0.34

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RZLT. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.08B
Alnylam Pharmaceuticals, Inc. operates in the biopharmaceutical field focusing on RNAi therapeutics for the treatment of rare genetic diseases, competing in the same rare disease space as Rezolute.
Ionis Pharmaceuticals
IONS
Mkt Cap6.98B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics, directly competing with Rezolute's approach to treating rare diseases through innovative therapies.
Akero Therapeutics
AKRO
Mkt Cap1.85B
Akero Therapeutics, Inc. focuses on developing treatments for serious metabolic diseases, closely aligning with Rezolute's mission in the metabolic disease sector.
Viking Therapeutics
VKTX
Mkt Cap5.61B
Viking Therapeutics, Inc. is involved in the development of therapies for metabolic and endocrine disorders, directly competing with Rezolute's metabolic disease focus.
Seres Therapeutics
MCRB
Mkt Cap185.52M
Seres Therapeutics, Inc. is engaged in microbiome therapeutics for metabolic diseases, which places it in direct competition with Rezolute's metabolic disease treatments.
FibroGen
FGEN
Mkt Cap104.45M
FibroGen, Inc. develops a pipeline of therapeutics that address unmet medical needs in anemia, fibrosis, and cancer, overlapping with Rezolute's focus on novel, underserved medical conditions.
Sage Therapeutics
SAGE
Mkt Cap739.64M
Sage Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to treat life-altering central nervous system (CNS) disorders, competing indirectly with Rezolute's broader focus on rare diseases.
PTC Therapeutics
PTCT
Mkt Cap2.5B
PTC Therapeutics, Inc. focuses on the discovery and commercialization of novel medicines to treat rare disorders, directly competing with Rezolute in the rare disease market.
Sarepta Therapeutics
SRPT
Mkt Cap13.76B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, competing in the rare disease space alongside Rezolute.

Analyst Ratings

11$Average Price Target
The highest estimate is $14.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

About

Internet Software/Services
Technology Services
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Show more...
CEO
Nevan Elam
Employees
41
Country
US
ISIN
US76200L3096

Listings

XNAS
US
RZLT